Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.

Metzger IF, Dave N, Kreutz Y, Lu JBL, Galinsky RE, Desta Z.

Clin Transl Sci. 2019 Jul 24. doi: 10.1111/cts.12671. [Epub ahead of print]

PMID:
31339646
2.

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL.

Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020.

PMID:
31190621
3.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale RF, Masimirembwa C, Iwuchukwu OF, Chirwa S, Lennox J, Gaedigk A, Klein TE, Haas DW.

Clin Pharmacol Ther. 2019 Apr 21. doi: 10.1002/cpt.1477. [Epub ahead of print]

PMID:
31006110
4.

Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors.

Liu SN, Lu JBL, Watson CJW, Lazarus P, Desta Z, Gufford BT.

Drug Metab Dispos. 2019 May;47(5):535-544. doi: 10.1124/dmd.118.085035. Epub 2019 Feb 25.

PMID:
30804050
5.

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.

Fulton CR, Zang Y, Desta Z, Rosenman MB, Holmes AM, Decker BS, Zhang Y, T Callaghan J, Pratt VM, Levy KD, Gufford BT, Dexter PR, Skaar TC, Eadon MT.

Pharmacogenomics. 2019 Apr;20(6):397-408. doi: 10.2217/pgs-2018-0205. Epub 2019 Feb 20.

PMID:
30784356
6.

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.

Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM.

Clin Pharmacol Ther. 2019 Jul;106(1):219-227. doi: 10.1002/cpt.1359. Epub 2019 Mar 18.

7.

Determination of antioxidant and antimicrobial activities of the extracts of aerial parts of Portulaca quadrifida.

Desta ZY, Cherie DA.

Chem Cent J. 2018 Dec 20;12(1):146. doi: 10.1186/s13065-018-0514-2.

8.

Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness.

Fulton CR, Swart M, De Luca T, Liu SN, Collins KS, Desta Z, Gufford BT, Eadon MT.

J Nurse Pract. 2018 Nov-Dec;14(10):697-704.e1. doi: 10.1016/j.nurpra.2018.09.021. Epub 2018 Nov 2. No abstract available.

PMID:
30555285
9.

DrugMetab: An Integrated Machine Learning and Lexicon Mapping Named Entity Recognition Method for Drug Metabolite.

Wu HY, Lu D, Hyder M, Zhang S, Quinney SK, Desta Z, Li L.

CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):709-717. doi: 10.1002/psp4.12340. Epub 2018 Sep 29.

10.

Determination of antioxidant and antimicrobial activities of leaf extracts of Otostegia integrifolia.

Chekol YA, Desta ZY.

Chem Cent J. 2018 May 18;12(1):63. doi: 10.1186/s13065-018-0433-2.

11.

Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes.

Gufford BT, Robarge JD, Eadon MT, Gao H, Lin H, Liu Y, Desta Z, Skaar TC.

Pharmacol Res Perspect. 2018 Mar 26;6(2):e00386. doi: 10.1002/prp2.386. eCollection 2018 Apr.

12.

CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.

Skaar TC, Desta Z.

Clin Pharmacol Ther. 2018 May;103(5):755-757. doi: 10.1002/cpt.1039. Epub 2018 Feb 23.

PMID:
29473149
13.

Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs.

Burgess KS, Ipe J, Swart M, Metzger IF, Lu J, Gufford BT, Thong N, Desta Z, Gaedigk R, Pearce RE, Gaedigk A, Liu Y, Skaar TC.

Clin Pharmacol Ther. 2018 Jul;104(1):130-138. doi: 10.1002/cpt.892. Epub 2017 Oct 25.

14.

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.

Marcath LA, Deal AM, Van Wieren E, Danko W, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL.

Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311.

15.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.

16.

Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial.

Pierson RC, Gufford BT, Desta Z, Eadon MT.

Pharmacogenomics. 2017 Jun;18(9):835-841. doi: 10.2217/pgs-2017-0042. Epub 2017 Jun 8.

17.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

18.

Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Robarge JD, Metzger IF, Lu J, Thong N, Skaar TC, Desta Z, Bies RR.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01813-16. doi: 10.1128/AAC.01813-16. Print 2017 Jan.

19.

Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.

20.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

21.

Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.

Abdelhady AM, Shugg T, Thong N, Lu JB, Kreutz Y, Jaynes HA, Robarge JD, Tisdale JE, Desta Z, Overholser BR.

J Cardiovasc Electrophysiol. 2016 Oct;27(10):1206-1213. doi: 10.1111/jce.13032. Epub 2016 Jul 25.

22.

Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z.

J Pharmacol Exp Ther. 2016 Aug;358(2):230-8. doi: 10.1124/jpet.116.232876. Epub 2016 Jun 2.

23.

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin WJ Jr.

Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.

24.

Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.

Benson EA, Eadon MT, Desta Z, Liu Y, Lin H, Burgess KS, Segar MW, Gaedigk A, Skaar TC.

Front Pharmacol. 2016 Apr 26;7:111. doi: 10.3389/fphar.2016.00111. eCollection 2016.

25.

Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.

Cho DY, Shen JH, Lemler SM, Skaar TC, Li L, Blievernicht J, Zanger UM, Kim KB, Shin JG, Flockhart DA, Desta Z.

Drug Metab Pharmacokinet. 2016 Apr;31(2):107-16. doi: 10.1016/j.dmpk.2015.07.002. Epub 2015 Jul 29.

26.

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.

Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.

27.

Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.

Masters AR, McCoy M, Jones DR, Desta Z.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Mar 15;1015-1016:201-208. doi: 10.1016/j.jchromb.2016.02.018. Epub 2016 Feb 18.

28.

Obituary: David Alastair Flockhart , MD, PhD.

Bies R, McDonald C, Desta Z.

Br J Clin Pharmacol. 2016 Feb;81(2):393-4. doi: 10.1111/bcp.12868. No abstract available.

29.

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.

Eadon MT, Desta Z, Levy KD, Decker BS, Pierson RC, Pratt VM, Callaghan JT, Rosenman MB, Carpenter JS, Holmes AM, McDonald CA, Benson EA, Patil AS, Vuppalanchi R, Gufford BT, Dave N, Robarge JD, Hyder MA, Haas DM, Kreutz RP, Dexter PR, Skaar TC, Flockhart DA.

Clin Pharmacol Ther. 2016 Jul;100(1):63-6. doi: 10.1002/cpt.347. Epub 2016 Mar 31. Review.

30.

Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z.

Drug Metab Dispos. 2016 Apr;44(4):544-53. doi: 10.1124/dmd.115.068908. Epub 2016 Jan 22. Erratum in: Drug Metab Dispos. 2016 Nov;44(11):1852.

31.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

32.

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).

Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.

33.

In Vitro Metabolism of Montelukast by Cytochrome P450s and UDP-Glucuronosyltransferases.

Cardoso Jde O, Oliveira RV, Lu JB, Desta Z.

Drug Metab Dispos. 2015 Dec;43(12):1905-16.

34.

A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice.

Eadon MT, Zhang H, Skaar TC, Hato T, Dagher PC, Gupta SK, Desta Z.

Antivir Chem Chemother. 2015 Apr;24(2):72-6. doi: 10.1177/2040206615595318. Epub 2015 Jul 30.

35.

Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.

Han X, Quinney SK, Wang Z, Zhang P, Duke J, Desta Z, Elmendorf JS, Flockhart DA, Li L.

Clin Pharmacol Ther. 2015 Sep;98(3):321-7. doi: 10.1002/cpt.150.

36.

Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver.

Burgess KS, Philips S, Benson EA, Desta Z, Gaedigk A, Gaedigk R, Segar MW, Liu Y, Skaar TC.

Clin Pharmacol Ther. 2015 Aug;98(2):205-15. doi: 10.1002/cpt.145.

37.

In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvin WJ Jr.

Br J Clin Pharmacol. 2015 Nov;80(5):1122-30. doi: 10.1111/bcp.12665. Epub 2015 Aug 2.

38.

Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.

Metzger IF, Quigg TC, Epstein N, Aregbe AO, Thong N, Callaghan JT, Flockhart DA, Nguyen AT, Stevens CK, Gupta SK, Desta Z.

Curr Ther Res Clin Exp. 2014 Sep 27;76:64-9. doi: 10.1016/j.curtheres.2014.05.002. eCollection 2014 Dec.

39.

Genome-wide discovery of drug-dependent human liver regulatory elements.

Smith RP, Eckalbar WL, Morrissey KM, Luizon MR, Hoffmann TJ, Sun X, Jones SL, Force Aldred S, Ramamoorthy A, Desta Z, Liu Y, Skaar TC, Trinklein ND, Giacomini KM, Ahituv N.

PLoS Genet. 2014 Oct 2;10(10):e1004648. doi: 10.1371/journal.pgen.1004648. eCollection 2014 Oct.

40.

Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.

Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM.

Steroids. 2015 Jul;99(Pt A):32-8. doi: 10.1016/j.steroids.2014.08.007. Epub 2014 Aug 24.

41.

Three new isoflavonoids from Erythrina caffra.

Desta ZY, Majinda RR.

Nat Prod Commun. 2014 Jun;9(6):817-20.

PMID:
25115087
42.

Genomic selection: genome-wide prediction in plant improvement.

Desta ZA, Ortiz R.

Trends Plant Sci. 2014 Sep;19(9):592-601. doi: 10.1016/j.tplants.2014.05.006. Epub 2014 Jun 23. Review.

PMID:
24970707
43.

Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.

Kreutz RP, Owens J, Lu D, Nystrom P, Jin Y, Kreutz Y, Desta Z, Flockhart DA.

Platelets. 2015;26(4):358-63. doi: 10.3109/09537104.2014.916793. Epub 2014 May 15.

44.

Prerequisites to implementing a pharmacogenomics program in a large health-care system.

Levy KD, Decker BS, Carpenter JS, Flockhart DA, Dexter PR, Desta Z, Skaar TC.

Clin Pharmacol Ther. 2014 Sep;96(3):307-9. doi: 10.1038/clpt.2014.101. Epub 2014 May 7.

45.

New flavonoids from the stem bark of Erythrina caffra Thunb.

Desta ZY, Sewald N, Majinda RR.

Nat Prod Res. 2014;28(9):667-73. doi: 10.1080/14786419.2014.895726. Epub 2014 Mar 25.

PMID:
24665834
46.

Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.

Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, Mushiroda T, Kamatani N, Ogburn E, Hall-Flavin D, Flockhart D, Nakamura Y, Mrazek DA, Weinshilboum RM.

Br J Clin Pharmacol. 2014 Aug;78(2):373-83. doi: 10.1111/bcp.12348.

47.

Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.

Kreutz RP, Bitar A, Owens J, Desta Z, Breall JA, von der Lohe E, Sinha A, Vatta M, Nystrom P, Jin Y, Flockhart DA.

J Thromb Thrombolysis. 2014 Oct;38(3):380-7. doi: 10.1007/s11239-014-1059-4.

48.

PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.

Lowenberg D, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Feb;24(2):133-8. doi: 10.1097/FPC.0000000000000019. No abstract available.

49.

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response.

Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang C, Kovacs RJ, Flockhart DA.

Clin Pharmacol. 2013 Dec 9;5:185-92. doi: 10.2147/CPAA.S53151. eCollection 2013.

50.

Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.

Abdelhady AM, Desta Z, Jiang F, Yeo CW, Shin JG, Overholser BR.

J Clin Pharmacol. 2014 Jan;54(1):87-96. doi: 10.1002/jcph.208. Epub 2013 Nov 19.

Supplemental Content

Support Center